Research Progress of the Role of EMT in EGFR-TKIs Resistance of Non-small Cell Lung Cancer.
YU Li, S Huang, LV Wang… - Chinese Journal of …, 2018 - search.ebscohost.com
Lung cancer is the one of the malignant tumor of the highest morbidity and mortality over the
world, and non-small cell lung cancer (NSCLC) makes up about 80%. Nowadays, molecular …
world, and non-small cell lung cancer (NSCLC) makes up about 80%. Nowadays, molecular …
培美曲塞单药或联合吉非替尼治疗EGFR-TKI 耐药后晚期非小细胞肺癌临床观察
刘红柳， 杨家梅 - 中国癌症杂志, 2017 - china-oncology.com
背景与目的: 生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine
kinase inhibitor, EGFR-TKI) 治疗晚期非小细胞肺癌(non-small cell lung cancer, NSCLC) …
kinase inhibitor, EGFR-TKI) 治疗晚期非小细胞肺癌(non-small cell lung cancer, NSCLC) …
[HTML][HTML] 上皮间质转化在非小细胞肺癌EGFR-TKIs 耐药中的研究进展
虞莉， 黄沙， 吕望， 何哲浩， 胡坚 - Chinese Journal of Lung Cancer, 2018 - ncbi.nlm.nih.gov
肺癌是全世界范围内发病率和死亡率最高的恶性肿瘤之一， 其中大约80% 是非小细胞肺癌（
non-small cell lung cancer, NSCLC）。 目前分子靶向治疗已成为NSCLC 的一线治疗方法 …
non-small cell lung cancer, NSCLC）。 目前分子靶向治疗已成为NSCLC 的一线治疗方法 …
Pemetrexed with gefitinib or pemetrexed alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors
LIU Hongliu, Y Jiamei - China Oncology, 2017 - china-oncology.com
Background and purpose: New treatment methods should be explored for non-small cell
lung cancer (NSCLC) patients with acquired resistance to epidermal growth factor receptor …
lung cancer (NSCLC) patients with acquired resistance to epidermal growth factor receptor …
YAP silencing reverses doxorubicin resistance in lung cancer cell line PC9 and its mechanism
GAO Hui, YIN Yujing, Q Aili - China Oncology, 2016 - china-oncology.com
Background and purpose: Drug resistance is a major cause of failure in lung cancer
chemotherapy. This study aimed to investigate the effect of YAP on doxorubicin resistance in …
chemotherapy. This study aimed to investigate the effect of YAP on doxorubicin resistance in …
沉默YAP 逆转肺癌PC9 细胞多柔比星耐药性及其机制研究
高辉， 殷玉敬， 钱爱丽 - 中国癌症杂志, 2016 - china-oncology.com
背景与目的: 耐药性是导致肺癌患者化疗失败的主要原因. 探讨YAP 对人肺癌PC9
细胞多柔比星耐药的逆转作用及其机制. 方法: 利用体外筛选方法从多柔比星敏感性肺癌细胞系 …
细胞多柔比星耐药的逆转作用及其机制. 方法: 利用体外筛选方法从多柔比星敏感性肺癌细胞系 …
盐酸埃克替尼与多西他赛, 培美曲塞不同联合方式对非小细胞肺癌PC-9 细胞系作用的实验研究
郭磊， 王键玮， 李爱洁， 汪进良， 刘欢… - Progress in Modern …, 2015 - search.ebscohost.com
摘要目的: 探讨盐酸埃克替尼以不同次序联合多西他赛, 培美曲塞对非小细胞肺癌细胞系PC-9
的作用. 方法: 运用xCELLigence 系统检验多西他赛, 培美曲塞, 盐酸埃克替尼单药作用于PC-9 …
的作用. 方法: 运用xCELLigence 系统检验多西他赛, 培美曲塞, 盐酸埃克替尼单药作用于PC-9 …